BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...December series A round with Arch Venture Partners; they were joined by Boyu Capital, General Atlantic, Sequoia Capital China...
...employees: 10Funds raised: $100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners,  Boyu General Atlantic, Sequoia Capital China...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...4-1BB and CTLA-4, and its investors include F-Prime Capital, Eight Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital China...
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...Authority, and existing investors CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, and Sequoia Capital China...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...investors including Boyu Capital, Matrix Partners China, Sequoia Capital China...
...$200 millionInvestors: Boyu Capital, Matrix Partners China, Sequoia Capital China...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital China...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...$67 million) in a series B round led by 3H Health Investment. Fellow new investors Sequoia Capital China...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

...Co. Ltd. (Shanghai:603259; HKEX:2359) led Simcha Therapeutics’ financing, which closed in May. Other investors included Sequoia Capital China...
...partners: N/A Number of employees: 0 Funds raised: $25 million Investors: WuXi AppTec Co. Ltd., Sequoia Capital China...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...Life Science Fund and Oriza Holdings as well as existing investors Loyal Valley Capital, Temasek, Sequoia Capital China...
BioCentury | Apr 9, 2020
Finance

Wuhan gene therapy play Neurophth raises $18M series A

...with plans to bring an ophthalmology gene therapy to market in three to five years. Sequoia Capital China...
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...China Equity Group and existing investors Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China...
Items per page:
1 - 10 of 49
BioCentury | Jan 22, 2021
Emerging Company Profile

SciNeuro reunites GSK R&D vets to bring CNS therapies to China

...December series A round with Arch Venture Partners; they were joined by Boyu Capital, General Atlantic, Sequoia Capital China...
...employees: 10Funds raised: $100 millionInvestors: Lilly Asia Ventures Fund, Arch Venture Partners,  Boyu General Atlantic, Sequoia Capital China...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...4-1BB and CTLA-4, and its investors include F-Prime Capital, Eight Roads, General Atlantic, GP Healthcare Capital, Sequoia Capital China...
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...Authority, and existing investors CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, and Sequoia Capital China...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

...investors including Boyu Capital, Matrix Partners China, Sequoia Capital China...
...$200 millionInvestors: Boyu Capital, Matrix Partners China, Sequoia Capital China...
BioCentury | Nov 17, 2020
Finance

D3 Bio’s debut with $200M series A highlights China’s fast-track to global stage

...A round Tuesday backed by a syndicate of investors including Boyu Capital, Matrix Partners China, Sequoia Capital China...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

...$67 million) in a series B round led by 3H Health Investment. Fellow new investors Sequoia Capital China...
BioCentury | Jun 25, 2020
Emerging Company Profile

Simcha launches with $25M WuXi-led series A, new take on IL-18 for cancer

...Co. Ltd. (Shanghai:603259; HKEX:2359) led Simcha Therapeutics’ financing, which closed in May. Other investors included Sequoia Capital China...
...partners: N/A Number of employees: 0 Funds raised: $25 million Investors: WuXi AppTec Co. Ltd., Sequoia Capital China...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...Life Science Fund and Oriza Holdings as well as existing investors Loyal Valley Capital, Temasek, Sequoia Capital China...
BioCentury | Apr 9, 2020
Finance

Wuhan gene therapy play Neurophth raises $18M series A

...with plans to bring an ophthalmology gene therapy to market in three to five years. Sequoia Capital China...
BioCentury | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

...China Equity Group and existing investors Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China...
Items per page:
1 - 10 of 49